Tech Company Financing Transactions
NuPathe Funding Round
NuPathe closed a $500 thousand funding round on 11/8/2005. Investors included BioAdvance Ventures.
Transaction Overview
Company Name
Announced On
11/8/2005
Transaction Type
Venture Equity
Amount
$500,000
Round
Undisclosed
Investors
BioAdvance Ventures (Lead Investor) (Barbara Schilberg)
Proceeds Purpose
We are
particularly pleased that our seed investors can also provide us with counsel and
expertise to help us accelerate the progress of the company, as we prepare to bring
NP101 into clinical trials and to expand our pipeline to address important medical needs
in schizophrenia and cognition.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
227 Washington Street 200
Conshohocken, PA 19428
USA
Conshohocken, PA 19428
USA
Phone
Website
Email Address
Overview
NuPathe Inc. is a specialty pharmaceutical company specializing in the acquisition and development of important and innovative therapeutic products in the area of neuroscience.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Armando Anido
Chief Financial Officer
Keith Goldan
Chief Scientific Officer
MarK Pierce
President
Terri Sebree
VP - General Counsel
Michael Marino
VP - Operations
Ezra Felker
Browse more venture capital transactions:
Prev: 11/8/2005: Portola Pharmaceuticals venture capital transaction
Next: 11/8/2005: Double Fusion venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs